119th Congress
H.R. 8205
Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
- Introduced
- In committee
- Passed House
- Passed Senate
- To President
- Became law
- Sponsor
- Mike Quigley(D-IL)
- Introduced
- Apr 6, 2026
- Policy area
- Health
- Committees
- House Committee on Energy and Commerce
- Official text
- Placed on Calendar Senate · Congress.gov page
Cosponsors (103)
Original cosponsors (1)
- Ken Calvert (R-CA)
Added later (102)
- Angie Craig (D-MN) · Apr 9, 2026
- Brian K. Fitzpatrick (R-PA) · Apr 9, 2026
- Jake Auchincloss (D-MA) · Apr 9, 2026
- Janice D. Schakowsky (D-IL) · Apr 9, 2026
- Michael T. McCaul (R-TX) · Apr 9, 2026
- Scott DesJarlais (R-TN) · Apr 9, 2026
- Bradley Scott Schneider (D-IL) · Apr 14, 2026
- David G. Valadao (R-CA) · Apr 14, 2026
- Glenn Thompson (R-PA) · Apr 14, 2026
- Gwen Moore (D-WI) · Apr 14, 2026
- Jason Crow (D-CO) · Apr 14, 2026
- Jeff Hurd (R-CO) · Apr 14, 2026
- David P. Joyce (R-OH) · Apr 15, 2026
- Marc A. Veasey (D-TX) · Apr 15, 2026
- Maria Elvira Salazar (R-FL) · Apr 15, 2026
- Suzanne Bonamici (D-OR) · Apr 15, 2026
- Andrew R. Garbarino (R-NY) · Apr 16, 2026
- Brad Sherman (D-CA) · Apr 16, 2026
- Gus M. Bilirakis (R-FL) · Apr 16, 2026
- Stephen F. Lynch (D-MA) · Apr 16, 2026
- Adam Smith (D-WA) · Apr 20, 2026
- Don Bacon (R-NE) · Apr 20, 2026
- Jay Obernolte (R-CA) · Apr 20, 2026
- Madeleine Dean (D-PA) · Apr 20, 2026
- Pete Sessions (R-TX) · Apr 20, 2026
- Steve Cohen (D-TN) · Apr 20, 2026
- Tom Cole (R-OK) · Apr 20, 2026
- Valerie P. Foushee (D-NC) · Apr 20, 2026
- John H. Rutherford (R-FL) · Apr 21, 2026
- Terri A. Sewell (D-AL) · Apr 21, 2026
- Danny K. Davis (D-IL) · Apr 22, 2026
- Joe Wilson (R-SC) · Apr 22, 2026
- Ritchie Torres (D-NY) · Apr 23, 2026
- Robert B. Aderholt (R-AL) · Apr 23, 2026
- Eleanor Holmes Norton (D-DC) · Apr 30, 2026
- Tracey Mann (R-KS) · Apr 30, 2026
- Jefferson Van Drew (R-NJ) · May 4, 2026
- Raja Krishnamoorthi (D-IL) · May 4, 2026
- Kim Schrier (D-WA) · May 7, 2026
- Lauren Underwood (D-IL) · May 7, 2026
- Mark Alford (R-MO) · May 7, 2026
- Nick LaLota (R-NY) · May 7, 2026
- Chuck Edwards (R-NC) · May 11, 2026
- Debbie Dingell (D-MI) · May 11, 2026
- Doris O. Matsui (D-CA) · May 11, 2026
- Young Kim (R-CA) · May 11, 2026
- Mike Bost (R-IL) · May 12, 2026
- Mike Thompson (D-CA) · May 12, 2026
- Paul Tonko (D-NY) · May 12, 2026
- Randy K. Weber, Sr. (R-TX) · May 12, 2026
- Rashida Tlaib (D-MI) · May 12, 2026
- Tim Walberg (R-MI) · May 12, 2026
- Stephanie I. Bice (R-OK) · May 13, 2026
- Suzan K. DelBene (D-WA) · May 13, 2026
- Darin LaHood (R-IL) · May 14, 2026
- J. Luis Correa (D-CA) · May 14, 2026
- Mario Diaz-Balart (R-FL) · May 14, 2026
- Timothy M. Kennedy (D-NY) · May 14, 2026
- George Whitesides (D-CA) · May 15, 2026
- Steve Womack (R-AR) · May 15, 2026
- David Rouzer (R-NC) · May 19, 2026
- Sanford D. Bishop, Jr. (D-GA) · May 19, 2026
- Julia Letlow (R-LA) · May 21, 2026
- Robin L. Kelly (D-IL) · May 21, 2026
- Josh Gottheimer (D-NJ) · May 26, 2026
- Mark E. Amodei (R-NV) · May 26, 2026
- Tim Moore (R-NC) · May 29, 2026
- Emanuel Cleaver (D-MO) · Jun 2, 2026
- Greg Stanton (D-AZ) · Jun 2, 2026
- John R. Carter (R-TX) · Jun 2, 2026
- Eugene Simon Vindman (D-VA) · Jun 10, 2026
- Robert J. Wittman (R-VA) · Jun 10, 2026
- Janelle S. Bynum (D-OR) · Jun 11, 2026
- Michael Guest (R-MS) · Jun 11, 2026
- Adelita S. Grijalva (D-AZ) · Jul 9, 2026
- Alma S. Adams (D-NC) · Jul 9, 2026
- Analilia Mejia (D-NJ) · Jul 9, 2026
- Bonnie Watson Coleman (D-NJ) · Jul 9, 2026
- Carol D. Miller (R-WV) · Jul 9, 2026
- Chellie Pingree (D-ME) · Jul 9, 2026
- Deborah K. Ross (D-NC) · Jul 9, 2026
- Donald G. Davis (D-NC) · Jul 9, 2026
- Eric Sorensen (D-IL) · Jul 9, 2026
- George Latimer (D-NY) · Jul 9, 2026
- Greg Landsman (D-OH) · Jul 9, 2026
- Herbert C. Conaway, Jr. (D-NJ) · Jul 9, 2026
- Jahana Hayes (D-CT) · Jul 9, 2026
- James A. Himes (D-CT) · Jul 9, 2026
- John B. Larson (D-CT) · Jul 9, 2026
- Jonathan L. Jackson (D-IL) · Jul 9, 2026
- Josh Riley (D-NY) · Jul 9, 2026
- Joyce Beatty (D-OH) · Jul 9, 2026
- Marcy Kaptur (D-OH) · Jul 9, 2026
- Mary Gay Scanlon (D-PA) · Jul 9, 2026
- Melanie A. Stansbury (D-NM) · Jul 9, 2026
- Nikki Budzinski (D-IL) · Jul 9, 2026
- Sarah McBride (D-DE) · Jul 9, 2026
- Scott H. Peters (D-CA) · Jul 9, 2026
- Sean Casten (D-IL) · Jul 9, 2026
- Seth Magaziner (D-RI) · Jul 9, 2026
- Thomas R. Suozzi (D-NY) · Jul 9, 2026
- Troy A. Carter (D-LA) · Jul 9, 2026
Summary
Summary by the Congressional Research Service· describes the “Reported to House” version
Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
This bill reauthorizes through FY2031 and revises programs that support research and development of drugs and other therapies to address amyotrophic lateral sclerosis (also known as ALS or Lou Gehrig's disease) and other neurodegenerative diseases.
The bill reauthorizes
• grants from the National Institutes of Health (NIH) for scientific research on investigational drugs to prevent or treat ALS for individuals not otherwise eligible for clinical trials,
• grants from the Food and Drug Administration (FDA) for research and development of therapies to prevent and treat ALS and other neurodegenerative diseases, and
• a Public-Private Partnership including the FDA and NIH that supports development and regulatory review of treatments for neurodegenerative diseases.
Also, the NIH, in considering renewal of its grants, must assess available information on the safety and efficacy of the investigational drugs. It must also require grantees to promptly report serious and unexpected adverse events associated with their investigational drugs.
Additionally, the FDA must publish a plan describing actions it will take over a five-year period to foster development of safe and effective drugs, and facilitate access to investigational drugs, that treat ALS and other rare neurodegenerative diseases. The FDA must also publish a report describing the actions it has taken under the plan.
Roll-call votes
No recorded votes on this bill.
Actions
- Sep 28, 2026 · Senate
Passed Senate without amendment by Voice Vote. (consideration: CR S5120) - Jul 23, 2026 · Senate
Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 466. - Jul 22, 2026 · House
Motion to reconsider laid on the table Agreed to without objection. - Jul 22, 2026 · House
On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. - Jul 22, 2026 · House
Considered as unfinished business. (consideration: CR H5159) - Jul 20, 2026 · House
At the conclusion of debate, the chair put the question on the motion to suspend the rules. Mr. Guthrie objected to the vote on the grounds that a quorum was not present. Further proceedings on the motion were postponed. The point of no quorum was considered as withdrawn. - Jul 20, 2026 · House
DEBATE - The House proceeded with forty minutes of debate on H.R. 8205. - Jul 20, 2026 · House
Considered under suspension of the rules. (consideration: CR H4652-4654; text: CR H4653) - Jul 20, 2026 · House
Mr. Guthrie moved to suspend the rules and pass the bill, as amended. - Jul 9, 2026 · House
Placed on the Union Calendar, Calendar No. 637. - Jul 9, 2026 · House
Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 119-733. - May 21, 2026
Ordered to be Reported (Amended) by the Yeas and Nays: 46 - 0. - May 21, 2026
Committee Consideration and Mark-up Session Held - May 13, 2026
Forwarded by Subcommittee to Full Committee by Voice Vote. - May 13, 2026
Subcommittee Consideration and Mark-up Session Held - Apr 6, 2026
Referred to the Subcommittee on Health. - Apr 6, 2026 · House
Referred to the House Committee on Energy and Commerce. - Apr 6, 2026
Introduced in House